An FDA notice posted August 6, 2026 lists an enlarged set of product codes for the recalled Hudson RCI Neonatal/Infant Heated Wire Breathing Circuits, which users are told to discard.
The agency's recall posting states Medline is not aware of any serious health consequences from use of the neonatal and infant heated wire breathing circuits it recalled nationwide.
The FDA says the recall concerns a heated wire connector that may discolor, melt, smoke or emit a burning odor at the Neptune humidifier; the company says it is not aware of any serious health consequences.
The federal recall notice, issued July 30, 2026, cites 34 reports of fire and directs owners to unplug the appliances until a free in-home repair is made.
The CPSC notice, recall number 26632, published July 30, 2026, also covers about 19,120 separately sold spring brakes and cites 21 reports of kit components breaking and 19 of brakes failing. It identifies the products by description alone — there are no codes for owners to check.
The agency's July 30, 2026 notice says the electrical cord can detach and ignite, and cites 555 reports of melting, sparking or smoking, 27 fires and 15 injuries.
The agency's July 30, 2026 notice says model NEW319A playsets violate the federal small parts ban; no injuries have been reported.
The agency's July 30, 2026 notice cites 22 reports of instability or tip-overs and 15 reported injuries, with a free repair kit offered.
The agency's July 30, 2026 notice says the model LT003 tower stools can collapse or tip over and that a child's torso can fit through openings on the front and back; no injuries have been reported.
The agency says the metal dressers, sold on Amazon, are unstable if not anchored to the wall and violate the mandatory clothing storage unit standard; no injuries have been reported.
A U.S. Consumer Product Safety Commission notice dated July 30, 2026 says the rockets can explode before reaching their intended height; no injuries have been reported.
The July 30, 2026 notice adds 195 green and purple loungers to an April 2026 recall, bringing the total to about 2,195.
The agency's July 30, 2026 notice says the dressers are unstable if not anchored to the wall and violate the mandatory clothing storage unit standard; no injuries have been reported.
A CPSC notice issued July 30, 2026 says the projectors' lithium-ion battery can overheat, with three overheating reports including one causing burns to a person's hands.
The July 30, 2026 recall notice cites an impalement hazard and a violation of the federal dive sticks ban; no injuries have been reported.
About 55,350 LED movie-theater souvenir cups and popcorn containers from Golden Link were recalled on July 30, 2026 over an ingestion hazard; no injuries have been reported.
The July 30, 2026 recall notice cites three reports of stools collapsing or tipping over and two injuries; a free repair kit is offered.
A U.S. Consumer Product Safety Commission notice dated July 30, 2026 says the lithium-ion batteries in the recalled hand warmers can overheat and ignite.
An FDA enforcement report lists the Class II recall, initiated June 11, 2026, as ongoing, citing hemostatic valve damage linked to dilator insertion during device preparation.
An FDA enforcement report classifies the ongoing action as Class II, the agency's middle category.
An FDA enforcement report lists a Class II, nationwide recall of one lot of 1% lidocaine HCl injection initiated on July 16, 2026.
An FDA enforcement record shows Green Jeeva LLC recalled 2,490 kg of bulk Organic Moringa Powder after the ingredient tested positive for salmonella; the recall is listed as ongoing.
An FDA enforcement report, recall number D-0711-2026, lists Major Pharmaceuticals recalling one lot of unit-dose levothyroxine tablets distributed nationwide, with the action listed as ongoing.
An FDA enforcement report lists 65,219 cartons of the over-the-counter eye drops recalled by Rohto-Mentholatum (Vietnam) Co., Ltd., with the action still ongoing.
An FDA enforcement report lists a Class II action covering six pulsed field ablation generators distributed in five European countries.
An FDA enforcement report dated July 29, 2026 lists the nationwide recall as ongoing and not yet classified.
An FDA enforcement report lists an ongoing recall over roller wear that, in the worst case, could leave a stretcher stuck on its rail.
The agency's enforcement record cites 300 lbs of 10 oz refrigerated won ton wrappers distributed to California restaurants and, via a wholesaler, to New Mexico grocery stores.
An ongoing recall of the single-use hospital catheter, initiated 3 June 2026, covers five lots distributed across the United States and 14 other countries, according to the FDA enforcement record.
An enforcement report dated July 29, 2026 records an ongoing recall of 1,219 bag-in-box units distributed in New York and New Jersey.
An FDA enforcement report lists an ongoing nationwide recall of unit-dose levothyroxine sodium tablets packaged and distributed by Major Pharmaceuticals, initiated July 13, 2026.
The enforcement record covers three units distributed in Texas, Missouri and Indiana and lists the action as ongoing.
AVID Medical, Inc. initiated the ongoing recall on May 19, 2026, according to the FDA's enforcement report.
An FDA enforcement report dated July 29, 2026 records an ongoing recall of unlabeled wonton wrappers distributed to California restaurants and, through a wholesaler, to New Mexico grocery stores. The record gives no lot numbers or date codes, and states the bags carry no ingredient labeling.
An FDA enforcement report lists an ongoing nationwide recall of one lot of amlodipine and olmesartan medoxomil tablets distributed by Ascend Laboratories over failed dissolution specifications.
An FDA enforcement report published July 29, 2026 lists one lot of 50 mcg levothyroxine sodium tablets recalled nationwide as a subpotent drug.
The agency's enforcement report lists one lot of the thyroid medication, distributed nationwide, as recalled for being subpotent; the action is ongoing.
An FDA enforcement report lists an ongoing recall by Medline Industries, LP of convenience kits containing recalled Bard Silastic Foley catheters, distributed in five states.
An FDA enforcement report lists an ongoing nationwide recall of one lot of Major Pharmaceuticals levothyroxine sodium tablets, initiated July 13, 2026.
An FDA enforcement report filed under recall number Z-2782-2026 lists 980 Medline convenience kits containing Bard Silastic Foley catheters, with the recall status ongoing.
An FDA enforcement report lists Micro Therapeutics, Inc. recalling Pipeline Flex Embolization Devices whose labeled implant length does not match the implant inside; the action is listed as ongoing.
An FDA enforcement report lists 45 kits recalled across 15 states because the packaged gynecology seal had passed its expiry date. The record carries no lot or serial numbers, so a matching catalogue number is the only identifier published; the action is listed as ongoing.
An FDA enforcement report lists the Class II action, initiated June 11, 2026, as ongoing after devices shipped with instructions omitting FARAPOINT PFA catheter information.
An FDA enforcement report lists an ongoing recall, initiated 17 June 2026, of a single lot of a sterile neurosurgical drainage kit distributed in 12 listed US states and Costa Rica.
An FDA enforcement report lists three lots of the 100-tablet unit-dose cartons recalled nationwide as subpotent, with the action ongoing.
Enforcement report D-0709-2026 lists an ongoing recall of 75 mcg levothyroxine sodium tablets packaged by Major Pharmaceuticals, initiated July 13, 2026.
The agency's enforcement report for recall Z-2747-2026 traces the action to a voluntary recall of a bupivacaine injection supplied within the kits.
The enforcement record cites an increased amount of raw material on the catheter surface; the action is listed as ongoing.
An FDA enforcement report classifies the ongoing Class II action, covering 3,465 units of the smartphone app, over missed-dose and high-glucose alerts that are not triggered at night under certain settings.
An FDA enforcement report classifies the ongoing recall as Class II, the agency's middle risk category.